Oppenheimer’s Jay Olson is liking the setup of TXMD shares more and more amid major commercial potential.
Cantor’s William Tanner explains that while TXMD asset TX-004 has magnetized the Street’s attention in the last half a year, TX-004 boasts a bigger commercial market.
Cantor’s William Tanner anticipates TXMD will turn to financing before the company’s VVA asset TX-04 faces its new PDUFA date with destiny: May 29, 2018.
Cantor’s William Tanner smirks as bears run low on “ammunition” to doubt TXMD on the heels of news of an NDA resubmission to the FDA for TX-004.
Billion-dollar Laurion fund initiates new positions in TEVA and TXMD.
Oppenheimer predicts TXMD to launch TX-004HR by mid-2018 with a January approval from the FDA.
TX-004 is on the path to FDA approval; Cantor’s William Tanner Sees 450% Upside.
These two pharma stocks all have upside of over 100% say top Wall Street analysts.
Oppenheimer analyst Jay Olson is out with a bullish research note on TherapeuticsMD Inc (NYSEMKT:TXMD), after a positive independent observational study conducted by the …
Cantor analyst William Tanner is out today with a few insights on TherapeuticsMD Inc (NYSEMKT:TXMD), after the drug maker announced the publication of a manuscript …
